verubecestat

Ligand id: 8699

Name: verubecestat

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 126.13
Molecular weight 409.1
XLogP 2.38
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
International Nonproprietary Names
INN number INN
10028 verubecestat
Synonyms
example 25 (US8940748) | SCH-900931
Database Links
CAS Registry No. 1286770-55-5
ChEMBL Ligand CHEMBL3301601
PubChem CID 51352361
RCSB PDB Ligand 66F
Search Google for chemical match using the InChIKey YHYKUSGACIYRML-KRWDZBQOSA-N
Search Google for chemicals with the same backbone YHYKUSGACIYRML
Search PubMed clinical trials verubecestat
Search PubMed titles verubecestat
Search PubMed titles/abstracts verubecestat
Search UniChem for chemical match using the InChIKey YHYKUSGACIYRML-KRWDZBQOSA-N
Search UniChem for chemicals with the same backbone YHYKUSGACIYRML
Comments
This is a new INN/USAN for a Merck BACE1 inhibitor for clinical trials in Alzheimer's disease (AD). However the relationship to MK-8931 (SCH 900931) is unclear. All three synonyms have become linked in some web instances but the structures of the two compounds are different.
Despite reaching Phase 3 clinical trial, Merck has announced (Feb 2017: Merck press release) termination of study NCT01739348 (in patients with mild-moderate AD) because they concluded there was no chance of achieving efficacy. This is the latest of a long list of BACE1 inhibitors to fail in AD. Their second Phase 3 trial, NCT01953601 (in prodromal AD), will continue, with results expected in early 2019.